BDBM253925 US10189849, Compound 28::US10927120, Compound 28::US9464092, Q::US9527857, Q::US9957276, Compound 28

SMILES O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(cn3)N3CCNCC3)nc21

InChI Key InChIKey=TWTKMJWAXOPXSX-UHFFFAOYSA-N

Data  17 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 17 hits for monomerid = 253925   

TargetCyclin-A1/Cyclin-dependent kinase 2(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 3.03E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 5.05E+4nMAssay Description:For the measurement of CDK2/cyclinE activity, enzyme (0.22 nM) was incubated with 100 mM ATP and the phosphoacceptor substrate peptide (1 mM) for one...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 5.05E+4nMAssay Description:Kinase enzymatic reactions were performed in 384-well microplates using a 12-channel Caliper LabChip instrument as a detection device. The enzymatic ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 5.05E+4nMAssay Description:Kinase enzymatic reactions were performed in 384-well microplates using a 12-channel Caliper LabChip instrument as a detection device. The enzymatic ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 3.03E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 0.600nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 1.08E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 0.627nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 0.600nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 0.600nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 1.08E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D3(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 4.38nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 3.03nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 1.08nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 0.627nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 3.03E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 1.08E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In DepthDetails
US Patent